

--CROSS REFERENCE TO RELATED APPLICATIONS

A 1
The present application is a divisional of application Serial Number
09/368,632 filed August 5, 1999.--

IN THE CLAIMS:

Please cancel Claims 1-20 and 22-28 before calculating the filing fee of this divisional application.

Please amend Claim 21 as follows:

A 2
21. (Amended) A pharmaceutical composition comprising the antibody of
any one of Claims 29-35.

Please add the following new Claims:

A 3
29. (New) An antibody directed against an isolated IL-16 antagonist peptide
consisting of CLLS (SEQ ID NO:2).

30. (New) An antibody directed against an isolated IL-16 antagonist peptide
consisting of any one of WQCLLS, WQALLS, VVQVVA or VKQVVA.

Sub B1
31. (New) An antibody directed against an isolated IL-16 antagonist peptide
consisting of GMWQLLS (SEQ ID NO:13).

32. (New) An antibody directed against an isolated IL-16 antagonist peptide
consisting of GMWQCLLSDSGQVLLE (SEQ ID NO:12).

33. (New) An antibody directed against an isolated IL-16 antagonist peptide
consisting of TGLWQCLLSEGD (SEQ ID NO:14).

34. (New) An antibody directed against an isolated IL-16 antagonist peptide
consisting of VSEEQKVVQVVA (SEQ ID NO:15).

35. (New) An antibody directed against an isolated IL-16 antagonist peptide
comprising Xaa₁-L-L-Xaa₂ wherein Xaa₁ and Xaa₂ is any amino acid (SEQ ID NO:1).